1.Prevalence of hepatitis viral markers in patients with hepatocellular carcinoma and extrahepatic neoplasm
Journal of Medical Research 2005;37(4):33-37
Objectives: studying the seroprevalence of HBsAg and anti-HCV in patients with hepatocellular carcinoma (HCC) and neoplasm of non-liver organs. Subjects and method: 124 patients with HCC and 284 patients with neoplasm of non-liver organs (i.e. stomach, colorectus and lung) were treated at Bach Mai Hospital and Viet Duc Hospital. This cross-sectional study was conductedfrom January 2002 to April 2003. Results: Out of 124 patients with HCC, HBsAg positive found in 95/124 (76.6%), anti- HCV positive found in 2/61 (3.28%), both HBsAg and anti-HCV posititive found in 1/61 (1.64%), and prevalence of anti-HCV is much lower than that of HBsAg, p<0.0001. Out of 284 patient with non-liver cancer, HBsAg posititive found in 33/284 (11.62%), and none among 179 patients has anti-HCV posititive. The prevalence of HBsAg posititive in HCC group is much higher than in non-liver cancer group (p<0.0001, OR=24.92).
Carcinoma, Hepatocellular, Neoplasms
2.Inferior vena cava and intra-cardiac invasion of hepatocellular carcinoma: a rare but catastrophic complication
Cynthia Assimta Peter ; Anand Swaroop Uppaluri ; Bak Siew Steven Wong
The Medical Journal of Malaysia 2017;72(1):58-59
Intra-cardiac extension of hepatocellular carcinoma (HCC) is
an uncommon but serious condition related to poor
prognosis. We report a 57-year-old male diagnosed with
HCC with intra-cardiac extension into the right atrium at
presentation. There were no symptoms related to cardiac
involvement and intra-cardiac extension was incidentally
noted on radiological imaging. He was offered palliative
treatment and succumbed to his disease within 50 days of
first diagnosis.
Carcinoma, Hepatocellular
;
Liver Neoplasms
5.Sarcomatous hepatocellular carcinoma: Two case reports and a review of Korean clinical literature.
Chang Min LEE ; Tae Hyo KIM ; Hyun Ju MIN ; Hyun Jin KIM ; Woon Tae JUNG ; Ok Jae LEE ; Gyung Hyuck KO
Korean Journal of Medicine 2009;77(Suppl 1):S41-S47
Sarcomatous hepatocellular carcinoma (HCC) is a rare primary liver cancer. Pathogenesis of sarcomatous transformation of HCC has not yet been elucidated. Sarcomatous HCC has highly invasive and metastatic potential, compared with ordinary HCC. We present here two cases of sarcomatous hepatocellular carcinoma with an unfavorable prognosis. Other cases reported in Korean literature of this uncommon tumor were also reviewed.
Carcinoma, Hepatocellular
;
Liver Neoplasms
;
Prognosis
6.The role of serum alpha feto-protein in the diagnosis and management of hepatocellular carcinoma
Journal of Practical Medicine 2003;458(8):42-45
Review and update some knowledge of alpha feto-protein (AFP) value in the diagnosis, prognosis and management of patients with hepatocellular carcinoma (HCC), and the role of AFP in monitoring of response to medical and surgical treatments. Serum AFP tests give sensitivity of 50% and specificity >90% at cut-off value of 500 ng/ml in the diagnosis of HCC in patients who had underlined hepatic diseases
Carcinoma, Hepatocellular
;
Liver
;
Liver Neoplasms
8.Expression of nm23 Protein in Human Gastric Carcinoma: correlation between nm23 expression with the development and metastasis of gastric carcinoma.
Jin Hee SOHN ; Hye Rym PARK ; Young Oui PARK
Korean Journal of Pathology 1996;30(6):487-494
Gene expression of nm23 has been investigated in many kinds of tumors, including breast cancers, colon cancers, hepatocellular carcinomas, papillary carcinomas of the thyroid and malignant melanomas since the nm23 was dislovered by Dr. Steeg as a tumor metastatic suppressor gene. Reduced expression of nm23 gene implicated in high metastatic potential in a variety of malignancies. However, there have been only a few reports on genetic alteration and expression of nm23 in human gastric carcinomas even though gastric carcinoma is a leading malignancy in Korea. In this study, we examined the expression of nm23 protein by immunohistochemistry in advanced and early gastric carcinomas, adenomas, matching normal mucosa to elucidate the role of nm23 in the development, progression and metastasis of human gastric carcinomas. The results are as follows; 1) Nm23 was expressed in 39 cases(69.6%) of 56 advanced gastric carcinomas. Among them, strong positive cases(grade 3) were 26(46.4%) and weak positive cases(grade 2) were 13(23.2%). 2) Nm23 expression was significantly different (P<0.05) depending on the site of the neoplasm. Antral carcinomas showed grade3 positivity in the 22/37 cases(60%), but carcinomas of the body showed negative (grade 1) result in about half(42.1%). 3) Nm23 expression was more intense in the neoplasm than normal mucosa.(67.9%) 4) Nm23 expression was not significantly related to the lymph node metastasis, invasion of lymphatics or veins and depth of invasion. 5) In the well differentiated carcinomas, grade3 were more common(64.0%). But in cases of signet ring cell carcinoma, many cases were negative(50.0%). 6) Nm23 expression rate and intensity was significantly increased from the normal mucosa to the gastric adenomas, early gastric carcinomas and advanced gastric carcinomas.
Humans
;
Carcinoma, Hepatocellular
;
Neoplasm Metastasis
;
Breast Neoplasms
9.Subclassification of Hepatocellular Carcinoma with Barcelona Clinic Liver Cancer Intermediate Stage.
Hye Won LEE ; Seung Up KIM ; Jun Yong PARK ; Do Young KIM ; Sang Hoon AHN ; Kwang Hyub HAN ; Beom Kyung KIM
Journal of Liver Cancer 2016;16(1):17-22
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer (BCLC) intermediate stage includes a highly heterogeneous population. Here, we aimed to sub-classify hepatocellular carcinoma with BCLC intermediate stage for better prognostification. METHODS: Between 2003 and 2008, 325 patients who were newly diagnosed as HCC with BCLC intermediate stage were considered eligible. Tumor factor and liver function were used for sub-classification. Overall survival (OS) was analyzed using Kaplan-Meier method with a comparison by log-rank test. RESULTS: A total of 325 patients with intermediate stage HCC were analyzed. Patients with tumor size ≥7 cm, tumor number ≥4 and Child-Pugh class B had the worse OS compared to those with tumor size <7 cm, tumor number <4 and Child-pugh class A, respectively (all P<0.05). These three variables affected the OS independently from multivariate Cox regression analysis (all P<0.05). So, using these three variables, patients were finally sub-classified as those with fulfilling none of three factors (B-a), one of three factors (B-b), two of three factors (B-c) and all of three factors (B-d) with the median OS of 39.2, 20.6, 12.0 and 8.3 months with statistical significances (all P<0.05 between B-a and B-b, between B-b and B-c, and between B-c and B-d), respectively. CONCLUSIONS: Sub-classification of HCC with BCLC intermediate stage may be useful in not only prognostification but also guidance of treatment strategies.
Carcinoma, Hepatocellular*
;
Humans
;
Liver Neoplasms*
;
Liver*
;
Prognosis